Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRABiotechnology
Healthcare
$0.37 -6.21%
-$0.10 today
- Market cap
- $69.21M
- Beta
- 2.76
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$1.24
52W Low $0.72High $3.65
Volume 1.50M
Average 2.02M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$241.16M
FY 2025 · Annual
Net Income
-$236.93M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 0 | 5M |
| Gross Profit | 0 | 0 | (668K) | 0 | (5M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 212.78M | 104.75M | 142.72M | 200.93M | 176.07M |
| Selling, General & Admin | 24.55M | 31.12M | 44.81M | 62.54M | 60.09M |
| Operating Expenses | 237.32M | 135.87M | 187.53M | 263.46M | 236.16M |
| Depreciation & Amortization | 538K | 594K | 668K | 631K | 208K |
| EBITDA | (236.77M) | (130.31M) | (234.99M) | (242.98M) | (233.37M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (237.32M) | (135.87M) | (188.19M) | (263.46M) | (241.16M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 4.56M | 16.61M | 19.93M | 8.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 3.22M |
| Other Income / Expenses | 11K | 4.97M | (47.46M) | 19.86M | 4.36M |
| Income Before Tax | (237.31M) | (130.9M) | (235.66M) | (243.61M) | (236.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 268K | 178K | 130K |
| Net Income | (237.31M) | (130.9M) | (235.93M) | (243.79M) | (236.93M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| EPS (Diluted) | (1.56) | (0.86) | (1.49) | (1.53) | (1.45) |
| 151.95M | 151.95M | 158.83M | 159.38M | 163.39M | |
| 151.95M | 151.95M | 158.83M | 159.38M | 163.39M |
NMRA Earnings Waterfall · TTM
NASDAQ:NMRA · Revenue to Net Income
Key Ratios
EPS$-1.33
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.2
P/S Ratio0.0
Analysis
$0 of revenue converted into -$222.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.33, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 30, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 21, 2026 |
How much revenue does NMRA generate?
Neumora Therapeutics, Inc. Common Stock (NMRA) reported $0.00 of revenue in fiscal 2025.
Is NMRA profitable?
Neumora Therapeutics, Inc. Common Stock (NMRA) reported -$236.93M of net income.
Continue the stock analysis
Jump to another research area for this company.